Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.
choosing a selection results in a full page refresh
Product has been added to your wishlist.
You can view your wishlist by creating or login account.
Please create account through ##customer_email## email
